Neoplasms, Plasma Cell: all 2,314 studies

Page 7 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.

• First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With VelcadeCompletedNCT01215344Phase 2Results posted
• Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01212952Phase 1/2Results posted
• Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65Active, not recruitingNCT01208662Phase 3Results posted
• Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple MyelomaTerminatedNCT01207765Phase 2Results posted
• Efficacy and Safety Study of SyB L-0501 for Patients With Multiple MyelomaTerminatedNCT01179490Phase 2Results posted
• Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple MyelomaCompletedNCT01177735Phase 2Results posted
• Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaTerminatedNCT01177683Phase 1/2Results posted
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT01177397Phase 1/2Results posted
• Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic TransplantTerminatedNCT01174082Phase 2Results posted
• Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple MyelomaCompletedNCT01160484Phase 2Results posted
• A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple MyelomaCompletedNCT01160380Phase 3Results posted
• Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory MyelomaCompletedNCT01159574Phase 2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01155583Phase 1/2Results posted
• Trial of Three Stem Cell Mobilization Regimens for Multiple MyelomaCompletedNCT01146834Phase 3Results posted
• Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple MyelomaCompletedNCT01142232Phase 1/2Results posted
• Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte InfusionsCompletedNCT01131169Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
• Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
• Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
• Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)CompletedNCT01109004Phase 3Results posted
• Aplidin - Dexamethasone in Relapsed/Refractory MyelomaCompletedNCT01102426Phase 3Results posted
• Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic MyelomaTerminatedNCT01096810Phase 2Results posted
• Dinaciclib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01096342Phase 2Results posted
• Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no ChemotherapyCompletedNCT01094548Phase 2Results posted
• Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple MyelomaCompletedNCT01090921Phase 2Results posted
• AZD6244 (Selumetinib) in Treating Patients With Multiple MyelomaCompletedNCT01085214Phase 2Results posted
• Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaCompletedNCT01083602Phase 2Results posted
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple MyelomaCompletedNCT01080391Phase 3Results posted
• Lenalidomide and High-Dose MelphalanCompletedNCT01079936Phase 1/2Results posted
• Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantTerminatedNCT01078441Phase 2Results posted
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01076270Not applicableResults posted
• Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell TransplantationCompletedNCT01066624Not applicableResults posted
• A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01063907Phase 1/2Results posted
• Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT01062230Phase 2Results posted
• Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple MyelomaCompletedNCT01057225Phase 1/2Results posted
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapyCompletedNCT01056276Phase 2Results posted
• Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple MyelomaCompletedNCT01054144Phase 2Results posted
• Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple MyelomaCompletedNCT01050790Not applicableResults posted
• Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01049945Phase 1/2Results posted
• Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple MyelomaCompletedNCT01045460Phase 2Results posted
• Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01034553Phase 1/2Results posted
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCompletedNCT01023308Phase 3Results posted
• Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsCompletedNCT01018979Phase 2Results posted
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 2Results posted
• Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01001442Phase 1/2Results posted
• Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple MyelomaCompletedNCT00999830Phase 2Results posted
• Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell TransplantCompletedNCT00998049Phase 2Results posted
• A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)CompletedNCT00985959Phase 1Results posted
• Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple MyelomaTerminatedNCT00985907Phase 1/2Results posted
• Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma PatientsTerminatedNCT00983346Phase 2Results posted
• Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of TherapyCompletedNCT00972959Phase 2Results posted
• Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00966693Phase 1/2Results posted
• Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT00963820Phase 1Results posted
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyCompletedNCT00950911Phase 3Results posted
• Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple MyelomaCompletedNCT00948922Phase 2Results posted
• Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple MyelomaTerminatedNCT00942422Phase 2Results posted
• Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00941720Phase 2Results posted
• Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple MyelomaCompletedNCT00932698Phase 1Results posted
• A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple MyelomaCompletedNCT00928486Phase 3Results posted
• Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00920855Phase 1/2Results posted
• A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple MyelomaTerminatedNCT00920556Phase 2Results posted
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
• Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple MyelomaCompletedNCT00916058Phase 1/2Results posted
• A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma PatientsCompletedNCT00911859Phase 2Results posted
• Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDCompletedNCT00908232Phase 2Results posted
• Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT00903968Phase 1/2Results posted
• Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple MyelomaTerminatedNCT00897910Results posted
• Acupuncture for Chemo-Induced Peripheral NeuropathyCompletedNCT00891618Phase 2Results posted
• A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple MyelomaCompletedNCT00872521Phase 2Results posted
• Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone InvolvementCompletedNCT00869206Phase 3Results posted
• Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)CompletedNCT00858234Phase 1Results posted
• Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple MyelomaTerminatedNCT00843310Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell TransplantCompletedNCT00839956Phase 2Results posted
• A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose ChemotherapyCompletedNCT00833560Phase 2Results posted
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic CancerTerminatedNCT00827099Phase 2Results posted
• Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple MyelomaCompletedNCT00813150Phase 3Results posted
• Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance LCompletedNCT00807599Phase 2Results posted
• Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
• Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding StudyTerminatedNCT00793650Phase 1/2Results posted
• Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaCompletedNCT00793572Phase 2Results posted
• Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple MyelomaCompletedNCT00792142Phase 2Results posted
• Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney DysfunctionTerminatedNCT00790842Phase 1/2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• Study Combining Bortezomib With High Dose Melphalan to Treat Multiple MyelomaCompletedNCT00784823Phase 1/2Results posted
• Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)CompletedNCT00773838Phase 2Results posted
• Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)CompletedNCT00773747Phase 3Results posted
• Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00772915Phase 2Results posted
• Trial of Romidepsin and Bortezomib for Multiple MyelomaTerminatedNCT00765102Phase 2Results posted
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure DisorderCompletedNCT00755040Phase 3Results posted
• Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)CompletedNCT00750815Phase 1/2Results posted
• A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple MyelomaCompletedNCT00747123Phase 2Results posted
• Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaCompletedNCT00743288Phase 1/2Results posted
• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaCompletedNCT00742560Phase 2Results posted
• Bortezomib With Melphalan and Prednisone for Multiple MyelomaCompletedNCT00734149Phase 2Results posted
• Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)CompletedNCT00732641Phase 3Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted

← Neoplasms, Plasma Cell overview